Bradley C. Carthon

Bradley C. Carthon

Hematology | Oncology
1365 Clifton Road Northeast
BldgC
Atlanta, GA 30322

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 87 publications

Novel Risk Scoring System for Patients with Metastatic Castration Resistant Prostate Cancer Treated with Lutetium-177-PSMA-617.

Novel Risk Scoring System for Patients with Metastatic Castration Resistant Prostate Cancer Treated with Lutetium-177-PSMA-617.

Journal: The oncologist
Published: June 01, 2026

Age Matters - Personalizing Treatment Intensification in Metastatic Hormone-Sensitive Prostate Cancer.

Age Matters - Personalizing Treatment Intensification in Metastatic Hormone-Sensitive Prostate Cancer.

Journal: NEJM evidence
Published: October 28, 2025

Evolving strategies in prostate cancer: Emerging approaches and unmet needs from the Bridging the Gaps in Prostate Cancer expert panel.

Evolving strategies in prostate cancer: Emerging approaches and unmet needs from the Bridging the Gaps in Prostate Cancer expert panel.

Journal: Cancer
Published: October 01, 2025

Inflammatory biomarkers have a prognostic role in patients with metastatic castration-resistant prostate cancer treated with Lutetium-177-PSMA-617.

Inflammatory biomarkers have a prognostic role in patients with metastatic castration-resistant prostate cancer treated with Lutetium-177-PSMA-617.

Journal: Cancer
Published: September 22, 2025

Clinical outcomes of lutetium-177-PSMA-617 in a racially diverse cohort of patients with metastatic castration-resistant prostate cancer.

Clinical outcomes of lutetium-177-PSMA-617 in a racially diverse cohort of patients with metastatic castration-resistant prostate cancer.

Journal: The oncologist
Published: July 16, 2025

Phase II Randomized Study of MK-2206 and Bicalutamide in Prostate Cancer Patients With Rising PSA After Primary Therapy (ECOG-ACRIN E2809).

Phase II Randomized Study of MK-2206 and Bicalutamide in Prostate Cancer Patients With Rising PSA After Primary Therapy (ECOG-ACRIN E2809).

Journal: The Prostate
Published: July 15, 2025

An increase in splenic volume after first-line immunotherapy is associated with worse PFS in patients with metastatic renal cell carcinoma.

An increase in splenic volume after first-line immunotherapy is associated with worse PFS in patients with metastatic renal cell carcinoma.

Journal: The oncologist
Published: July 15, 2025

Overcoming resistance in advanced urothelial carcinoma: mechanisms of escape from antibody-drug conjugates and FGFR3 inhibition.

Overcoming resistance in advanced urothelial carcinoma: mechanisms of escape from antibody-drug conjugates and FGFR3 inhibition.

Journal: Frontiers in oncology
Published: June 26, 2025

Somatic yolk sac tumors in the urinary tract: A form of rare divergent differentiation.

Somatic yolk sac tumors in the urinary tract: A form of rare divergent differentiation.

Journal: Human pathology
Published: May 30, 2025

Phase I study of palbociclib with cisplatin or carboplatin in the management of patients with advanced pancreatic cancer.

Phase I study of palbociclib with cisplatin or carboplatin in the management of patients with advanced pancreatic cancer.

Journal: The oncologist
Published: February 07, 2025

Baseline geriatric 8 (G8) screening tool predicts overall survival in metastatic urothelial carcinoma treated with immune checkpoint inhibitors.

Baseline geriatric 8 (G8) screening tool predicts overall survival in metastatic urothelial carcinoma treated with immune checkpoint inhibitors.

Journal: The oncologist
Published: February 06, 2025

Characteristics, Treatment, and Outcomes of Primary Urethral Cancer: A Multicenter Review Over Two Decades.

Characteristics, Treatment, and Outcomes of Primary Urethral Cancer: A Multicenter Review Over Two Decades.

Journal: Clinical genitourinary cancer
Published: October 15, 2024
Showing 1-12 of 87

Last Updated: 09/26/2026